Elekta
Market Cap
kr29.4b
Last Updated
2020/03/27 20:50 UTC
Data Sources
Company Financials +
Executive Summary
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Good value with reasonable growth potential and pays a dividend.
Similar Companies
Share Price & News
How has Elekta's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EKTA B's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
10.1%
EKTA B
3.7%
SE Medical Equipment
4.5%
SE Market
1 Year Return
-33.4%
EKTA B
5.9%
SE Medical Equipment
-10.2%
SE Market
Return vs Industry: EKTA B underperformed the Swedish Medical Equipment industry which returned 8.1% over the past year.
Return vs Market: EKTA B underperformed the Swedish Market which returned -7.1% over the past year.
Shareholder returns
| EKTA B | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.1% | 3.7% | 4.5% |
| 30 Day | -30.0% | -14.2% | -23.1% |
| 90 Day | -37.3% | -17.7% | -23.8% |
| 1 Year | -32.4%-33.4% | 7.6%5.9% | -7.4%-10.2% |
| 3 Year | -8.5%-12.2% | 26.4%12.0% | -0.2%-15.4% |
| 5 Year | 4.3%-1.4% | 24.1%3.2% | 8.5%-14.7% |
Price Volatility Vs. Market
How volatile is Elekta's share price compared to the market and industry in the last 5 years?
Simply Wall St News
17 hours ago | Simply Wall St
Boasting A 15% Return On Equity, Is Elekta AB (publ) (STO:EKTA B) A Top Quality Stock?1 week ago | Simply Wall St
John Lapré Just Bought Shares In Elekta AB (publ) (STO:EKTA B)2 weeks ago | Simply Wall St
What Is Elekta's (STO:EKTA B) P/E Ratio After Its Share Price Tanked?Valuation
Is Elekta undervalued compared to its fair value and its price relative to the market?
46.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EKTA B (SEK77) is trading below our estimate of fair value (SEK143.74)
Significantly Below Fair Value: EKTA B is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EKTA B is good value based on its PE Ratio (24.3x) compared to the Medical Equipment industry average (48.8x).
PE vs Market: EKTA B is poor value based on its PE Ratio (24.3x) compared to the Swedish market (14.4x).
Price to Earnings Growth Ratio
PEG Ratio: EKTA B is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: EKTA B is good value based on its PB Ratio (3.6x) compared to the SE Medical Equipment industry average (3.6x).
Next Steps
Future Growth
How is Elekta forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
18.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EKTA B's forecast earnings growth (18.8% per year) is above the savings rate (-0.4%).
Earnings vs Market: EKTA B's earnings (18.8% per year) are forecast to grow faster than the Swedish market (7.8% per year).
High Growth Earnings: EKTA B's earnings are forecast to grow, but not significantly.
Revenue vs Market: EKTA B's revenue (8.9% per year) is forecast to grow faster than the Swedish market (4.1% per year).
High Growth Revenue: EKTA B's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EKTA B's Return on Equity is forecast to be high in 3 years time (20.6%)
Next Steps
Past Performance
How has Elekta performed over the past 5 years?
26.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKTA B has high quality earnings.
Growing Profit Margin: EKTA B's current net profit margins (8.3%) are lower than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: EKTA B's earnings have grown significantly by 26.2% per year over the past 5 years.
Accelerating Growth: EKTA B's earnings growth over the past year (4.1%) is below its 5-year average (26.2% per year).
Earnings vs Industry: EKTA B earnings growth over the past year (4.1%) underperformed the Medical Equipment industry 12.6%.
Return on Equity
High ROE: EKTA B's Return on Equity (14.8%) is considered low.
Next Steps
Financial Health
How is Elekta's financial position?
Financial Position Analysis
Short Term Liabilities: EKTA B's short term assets (SEK12.5B) do not cover its short term liabilities (SEK12.5B).
Long Term Liabilities: EKTA B's short term assets (SEK12.5B) exceed its long term liabilities (SEK4.5B).
Debt to Equity History and Analysis
Debt Level: EKTA B's debt to equity ratio (56.1%) is considered high.
Reducing Debt: EKTA B's debt to equity ratio has reduced from 81% to 56.1% over the past 5 years.
Debt Coverage: EKTA B's debt is well covered by operating cash flow (28.6%).
Interest Coverage: EKTA B's interest payments on its debt are well covered by EBIT (15.9x coverage).
Balance Sheet
Inventory Level: EKTA B has a high level of physical assets or inventory.
Debt Coverage by Assets: EKTA B's debt is covered by short term assets (assets are 2.7x debt).
Next Steps
Dividend
What is Elekta's current dividend yield, its reliability and sustainability?
2.34%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EKTA B's dividend (2.34%) is higher than the bottom 25% of dividend payers in the Swedish market (2.1%).
High Dividend: EKTA B's dividend (2.34%) is low compared to the top 25% of dividend payers in the Swedish market (6.51%).
Stability and Growth of Payments
Stable Dividend: EKTA B's dividend payments have been volatile in the past 10 years.
Growing Dividend: EKTA B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (56.7%), EKTA B's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EKTA B's dividends in 3 years are forecast to be well covered by earnings (43% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Richard Hausmann (59yo)
3.75s
Tenure
kr14,820,000
Compensation
Dr. Richard Hausmann, Ph.D. has been the Chief Executive Officer and President of Elekta AB (publ) since June 10, 2016. Dr. Hausmann has been Vice President at General Electric Company since January 1, 201 ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD0.00) is below average for companies of similar size in the Swedish market ($USD1.37M).
Compensation vs Earnings: Richard's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 6.5yrs | kr1.28m | 6.03% SEK1.8b | |
| President & CEO | 3.75yrs | kr14.82m | 0.016% SEK4.8m | |
| CFO & Executive VP | 2.67yrs | no data | 0.00055% SEK161.8k | |
| Chief Operating Officer | 2.5yrs | no data | no data | |
| Head of Investor Relations | 0.83yr | no data | no data | |
| Senior VP | 5.5yrs | no data | no data | |
| General Counsel | 3.33yrs | no data | 0.000050% SEK14.7k | |
| Chief Marketing & Sales Officer | 2.58yrs | no data | no data | |
| Executive Vice President of Human Resources | 3.17yrs | no data | no data | |
| Head of External Relations | 4.67yrs | no data | no data |
3.2yrs
Average Tenure
53yo
Average Age
Experienced Management: EKTA B's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 6.5yrs | kr1.28m | 6.03% SEK1.8b | |
| Independent Director | 10.17yrs | kr635.00k | 0.0075% SEK2.2m | |
| Independent Director | 9.17yrs | kr575.00k | 0.0046% SEK1.3m | |
| Non-Executive Director | 7.17yrs | kr500.00k | 0.16% SEK46.2m | |
| Independent Director | 5.17yrs | kr635.00k | 0.0052% SEK1.5m | |
| Independent Director | 15.17yrs | kr725.00k | 0.0016% SEK470.7k | |
| Director | 2.58yrs | kr635.00k | 0.048% SEK14.0m | |
| Independent Director | 1.58yrs | kr575.00k | 0.00026% SEK76.5k |
6.8yrs
Average Tenure
62yo
Average Age
Experienced Board: EKTA B's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EKTA B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Elekta AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Elekta AB (publ)
- Ticker: EKTA B
- Exchange: OM
- Founded: 1972
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr29.420b
- Shares outstanding: 382.08m
- Website: https://www.elekta.com
Number of Employees
Location
- Elekta AB (publ)
- Box 7593
- Kungstensgatan 18
- Stockholm
- Stockholm County
- 103 93
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EKTA.F | OTCPK (Pink Sheets LLC) | Yes | Series B Registered Shares | US | USD | Mar 1994 |
| EKTA B | OM (OMX Nordic Exchange Stockholm) | Yes | Series B Registered Shares | SE | SEK | Mar 1994 |
| EJXB | DB (Deutsche Boerse AG) | Yes | Series B Registered Shares | DE | EUR | Mar 1994 |
| 0O5H | LSE (London Stock Exchange) | Yes | Series B Registered Shares | GB | SEK | Mar 1994 |
| EKTABS | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Series B Registered Shares | GB | SEK | Mar 1994 |
| EKTA.Y | OTCPK (Pink Sheets LLC) | UNSPONSOD ADR | US | USD | Dec 2008 |
Biography
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/27 20:50 |
| End of Day Share Price | 2020/03/27 00:00 |
| Earnings | 2020/01/31 |
| Annual Earnings | 2019/04/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.